Literature DB >> 10713102

TrkA amino acids controlling specificity for nerve growth factor.

L O'Connell1, J A Hongo, L G Presta, P Tsoulfas.   

Abstract

Neurotrophins are important for the development and maintenance of the vertebrate nervous system, mediating their signal into the cell by specific interaction with tyrosine kinase receptors of the Trk family. The extracellular portion of the Trk receptors has been previously proposed to consist of a cysteine-rich motif, a leucine-rich motif, a second cysteine-rich motif followed by two immunoglobulin-like domains. Earlier studies have shown that a major neurotrophin-binding site in the Trk receptors resides in the second immunoglobulin-like domain. Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear. In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA. The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB. This implies that the amino acids in the second immunoglobulin-like domain that determine Trk specificity are distinct for each Trk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713102     DOI: 10.1074/jbc.275.11.7870

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

1.  Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.

Authors:  Sung-Wuk Jang; Xia Liu; Chi-Bun Chan; David Weinshenker; Randy A Hall; Ge Xiao; Keqiang Ye
Journal:  Chem Biol       Date:  2009-06-26

Review 2.  Trk receptor expression and inhibition in neuroblastomas.

Authors:  Garrett M Brodeur; Jane E Minturn; Ruth Ho; Anisha M Simpson; Radhika Iyer; Carly R Varela; Jennifer E Light; Venkatadri Kolla; Audrey E Evans
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

3.  Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor.

Authors:  Lisa A Majuta; Geraldine Longo; Michelle N Fealk; Gwen McCaffrey; Patrick W Mantyh
Journal:  Pain       Date:  2015-01       Impact factor: 7.926

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.